Clinical trial registry record

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 26, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05260021
Last registry update
September 26, 2025
Status
Completed
Phase
Phase 3
Sponsor
Eli Lilly and Company
Enrollment
99
Countries
United States, Australia, Brazil, France, India, Israel, Italy, Mexico, United Kingdom
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
Evidence population
Human clinical study registration
Participants
99
Population
ALL · 10 Years to 18 Years
Duration
2022-04-13 to 2025-01-28
Intervention
Tirzepatide Dose 1; Tirzepatide Dose 2; Placebo
Comparator
Placebo
Outcomes measured
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) — Baseline, Week 30; Change From Baseline in HbA1c (Individual Doses) — Baseline, Week 30; Percentage of Participants Who Achieve ≤6.5% of HbA1c — Week 30; Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (Age and Sex-matched) — Baseline, Week 30; Change From Baseline in Fasting Serum Glucose (FSG) — Baseline, Week 30; Percent Change From Baseline in BMI — Baseline, Week 30; Percentage of Participants Who Achieve <5.7% of HbA1c — Week 30; Percentage of Participants Who Achieve <7.0% of HbA1c — Week 30; Percent Change From Baseline for Serum Lipid Levels — Baseline, Week 30; Change From Baseline in Height Standard Deviation Score (SDS) — Baseline, Week 30; Change From Baseline in Weight SDS — Baseline, Week 30; Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale — Baseline, Week 52; Change From Baseline PedsQL (3.2) Diabetic Module — Baseline, Week 52; Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide — Week 0: aft…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Metformin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

metformin
Read the original source →Export JSON